Stockscreener 앱 받기
5.25
3.70%
-0.16
전일 마감가:
$5.41
열려 있는:
$5.41
하루 거래량:
486.69K
Relative Volume:
0.41
시가총액:
$839.43M
수익:
$62.04M
순이익/손실:
$-533.34M
주가수익비율:
-1.3393
EPS:
-3.92
순현금흐름:
$-473.07M
1주 성능:
-15.42%
1개월 성능:
-8.92%
6개월 성능:
-45.73%
1년 성능:
-45.50%
1일 변동 폭
$5.08
$5.45
1주일 범위
$5.04
$6.29
52주 변동 폭
$4.95
$14.45
비르 바이오테크 Stock (VIR) Company Profile
명칭
Vir Biotechnology Inc
전화
415-906-4324
주소
1800 OWENS STREET, SAN FRANCISCO, CA
VIR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.24 | 839.43M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.67 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.81 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
547.58 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.01 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
230.82 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
비르 바이오테크 Stock (VIR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-03-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-02-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 개시 | SVB Leerink | Outperform |
| 2022-09-09 | 개시 | Morgan Stanley | Underweight |
| 2022-03-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-01-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-09-14 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-11 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 개시 | Needham | Buy |
| 2020-03-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-02-27 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 개시 | Robert W. Baird | Neutral |
| 2019-11-05 | 개시 | Barclays | Overweight |
| 2019-11-05 | 개시 | Cowen | Outperform |
| 2019-11-05 | 개시 | Goldman | Buy |
| 2019-11-05 | 개시 | JP Morgan | Overweight |
모두보기
비르 바이오테크 주식(VIR)의 최신 뉴스
Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus
Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey
Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha
Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks
Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - Business Wire
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha
Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN
Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks
Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Advancements - GuruFocus
Vir Biotechnology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - BioSpace
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
Earnings call transcript: Vir Biotech Q1 2025 reports increased R&D expenses - Investing.com
Vir Biotechnology (VIR) Falls Short on Q1 Revenue, Advances Clinical Programs | VIR Stock News - GuruFocus
Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 1c - StreetInsider
Vir Biotechnology Q1 2025 Earnings Preview - MSN
Earnings Outlook For Vir Biotechnology - Nasdaq
Vir Biotechnology Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView
(VIR) On The My Stocks Page - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Vir Biotechnology Inc. - GuruFocus
Will Vir Biotech's Hepatitis B And D Data Presentations Give The Stock A Much-Needed Boost? - RTTNews
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 - BioSpace
Vir Biotechnology SVP sells shares for $14,291 - MSN
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver Congress 2025 - marketscreener.com
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 - BioSpace
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | VIR Stock News - GuruFocus
When (VIR) Moves Investors should Listen - news.stocktradersdaily.com
5 Analysts Have This To Say About Vir Biotechnology - Benzinga
Lobbying Update: $50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed - Nasdaq
New Mpro inhibitors revealed in Vir Biotechnology patent - BioWorld MedTech
Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple - Insider Monkey
10 Stocks Under $10 that Will Triple - Insider Monkey
Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock By Investing.com - Investing.com South Africa
Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock - Investing.com
Vir Biotechnology CEO Sells Shares to Cover Tax Obligations - TradingView
Vir Biotechnology stock hits 52-week low at $6.07 By Investing.com - Investing.com Australia
Vir Biotechnology stock hits 52-week low at $6.07 - Investing.com
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution - simplywall.st
Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo
Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India
(VIR) Trading Advice - news.stocktradersdaily.com
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow
Brii Bio Secures 4-Year Cash Runway Despite Wider Losses: Key HBV Trial Success - Stock Titan
Hepatitis D Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com
(VIR) Trading Signals - Stock Traders Daily
비르 바이오테크 (VIR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.11%
0.83%
자본화:
|
볼륨(24시간):